{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:40:52Z","timestamp":1777088452082,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in the\n                    <jats:italic>GBA1<\/jats:italic>\n                    gene, encoding beta\u2010glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's Disease (PD). BIA 28\u20136156, an allosteric activator of GCase, is under development for the treatment of GBA\u2010associated PD. This Phase 1, randomized, double\u2010blind, placebo\u2010controlled, crossover study assessed the impact of BIA 28\u20136156 on QT interval corrected (QTc) for heart rate (HR) based on the Fridericia correction (QTcF) in 37 healthy subjects. Participants received single doses of 60 or 150\u00a0mg BIA 28\u20136156, 400\u00a0mg moxifloxacin, or placebo in a cross\u2010over design. The relationship between BIA 28\u20136156 plasma levels and QTcF changes (\u0394QTcF) was analyzed to exclude a \u0394\u0394QTcF &gt;\u00a010 ms. Heart rate, PR, and QRS intervals, electrocardiogram (ECG) waveform morphology, and adverse events (AEs) were also evaluated. The concentration\u2010QTc analysis indicated no effect on \u0394\u0394QTcF exceeding 10\u00a0ms up to BIA 28\u20136156 plasma levels of \u22487150\u00a0ng\/mL. No clinically significant effects on ECG parameters were observed, and BIA 28\u20136156 was generally well tolerated, with no deaths or serious AEs. This study concluded that BIA 28\u20136156 has no clinically relevant impact on ECG parameters, confirming a negative thorough QT\/QTc study.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.70055","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:46:10Z","timestamp":1775792770000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Randomized, Double\u2010Blinded, Placebo\u2010Controlled QTc Study to Evaluate BIA 28\u20136156 Effect on Cardiac Repolarization in Healthy Volunteers"],"prefix":"10.1002","volume":"15","author":[{"given":"Isa","family":"Peixoto","sequence":"first","affiliation":[{"name":"Research &amp; Development BIAL\u2010Portela &amp; C<sup>a<\/sup>, S.A  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Hilt","sequence":"additional","affiliation":[{"name":"Actinogen Medical  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Research &amp; Development BIAL\u2010Portela &amp; C<sup>a<\/sup>, S.A  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Reis","sequence":"additional","affiliation":[{"name":"Research &amp; Development BIAL\u2010Portela &amp; C<sup>a<\/sup>, S.A  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[{"name":"Research &amp; Development BIAL\u2010Portela &amp; C<sup>a<\/sup>, S.A  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Holenz","sequence":"additional","affiliation":[{"name":"Research &amp; Development BIAL\u2010Portela &amp; C<sup>a<\/sup>, S.A  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25535"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.1274"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-010-9095-5"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.971252"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24777"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000276989.17578.02"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108419"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-022-02531-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14387"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12309"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.04.022"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.10.006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001315"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61522-6"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2013006060"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24781"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26359"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28342"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a124284"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.12.014"},{"key":"e_1_2_9_22_1","first-page":"s1","article-title":"Design of a time\u2010to\u2010event study in GBA1 Parkinson's disease patients: efficacy and safety of BIA 28\u20136156, an allosteric activator of beta\u2010glucocerebrosidase (GCase)","volume":"38","author":"Magalh\u00e3es LM","year":"2023","journal-title":"Mov Disord"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29346"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00427.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03660.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1408-1"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00487.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111482"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-474X.2006.00082.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/323015"},{"key":"e_1_2_9_31_1","unstructured":"European Medicines Agency.ICH Topic E14:the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. November 2005.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010e\u201014\u2010clinical\u2010evaluation\u2010qtqts\u2010interval\u2010prolongation\u2010and\u2010proarrhythmic\u2010potential\u2010non\u2010antiarrhythmic\u2010drugs\u2010step\u20105_en.pdf. Accessed in November 18 2025."},{"key":"e_1_2_9_32_1","first-page":"61134","article-title":"International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs; availability","volume":"70","author":"Food and Drug Administration","year":"2005","journal-title":"otice. Fed Regist"},{"key":"e_1_2_9_33_1","unstructured":"European Medicines Agency.ICH guideline E14: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs (R3) \u2013 questions and answers. June 2017.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010guideline\u2010e14\u2010clinical\u2010evaluation\u2010qtqtc\u2010interval\u2010prolongation\u2010and\u2010proarrhythmic\u2010potential\u2010non\u2010antiarrhythmic\u2010drugs\u2010r3\u2010questions\u2010and\u2010answers\u2010step\u20105_en.pdf. Accessed in November 18 2025."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528110-00003"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70055","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:09:02Z","timestamp":1777086542000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/cpdd.70055"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70055","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70055"}}